Verrica Pharmaceuticals (NASDAQ:VRCA) CMO Noah Rosenberg Purchases 4,200 Shares of Stock

Key Points

• Verrica Pharmaceuticals CMO Noah Rosenberg purchased 4,200 shares at an average price of $4.91, investing $20,622 and increasing his direct ownership by 178.19% to 6,557 shares.
• VRCA shares fell $0.21 to $4.68, with the stock trading below its 50-day and 200-day moving averages. The company has an approximately $80.4 million market capitalization and a one-year trading range of $3.28 to $9.82.
• Analyst sentiment is mixed, resulting in a consensus “Hold” rating and a $14.50 price target; institutional investors own 42.45% of the company’s shares.

Verrica Pharmaceuticals Inc. (NASDAQ:VRCA - Get Free Report) CMO Noah Rosenberg bought 4,200 shares of the business's stock in a transaction dated Monday, August 17th. The stock was acquired at an average cost of $4.91 per share, for a total transaction of $20,622.00. Following the completion of the acquisition, the chief marketing officer directly owned 6,557 shares in the company, valued at approximately $32,194.87. This trade represents a 178.19% increase in their ownership of the stock. The purchase was disclosed in a filing with the Securities & Exchange Commission, which is available at this link.

Verrica Pharmaceuticals Stock Performance

VRCA stock traded down $0.21 on Tuesday, hitting $4.68. The company's stock had a trading volume of 46,708 shares, compared to its average volume of 92,498. The stock has a market cap of $80.40 million, a price-to-earnings ratio of -2.80 and a beta of 1.49. The firm has a 50 day moving average of $5.68 and a two-hundred day moving average of $5.93. The company has a current ratio of 1.45, a quick ratio of 1.33 and a debt-to-equity ratio of 0.18. Verrica Pharmaceuticals Inc. has a 1 year low of $3.28 and a 1 year high of $9.82.

Wall Street Analyst Weigh In

A number of brokerages have recently commented on VRCA. Wall Street Zen cut shares of Verrica Pharmaceuticals from a "sell" rating to a "strong sell" rating in a report on Saturday. Weiss Ratings reissued a "sell (e+)" rating on shares of Verrica Pharmaceuticals in a report on Wednesday, July 15th. HC Wainwright began coverage on Verrica Pharmaceuticals in a research report on Tuesday, May 26th. They issued a "buy" rating and a $12.00 price target on the stock. Finally, Zacks Research raised Verrica Pharmaceuticals from a "strong sell" rating to a "hold" rating in a research note on Monday, May 11th. Two investment analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has issued a Sell rating to the company. According to MarketBeat.com, the company presently has a consensus rating of "Hold" and a consensus price target of $14.50.

Hedge Funds Weigh In On Verrica Pharmaceuticals

A number of large investors have recently bought and sold shares of VRCA. AQR Capital Management LLC raised its position in Verrica Pharmaceuticals by 306.7% during the 1st quarter. AQR Capital Management LLC now owns 58,711 shares of the company's stock worth $26,000 after buying an additional 44,275 shares during the last quarter. Qube Research & Technologies Ltd purchased a new stake in shares of Verrica Pharmaceuticals in the second quarter valued at about $28,000. Invesco Ltd. increased its stake in shares of Verrica Pharmaceuticals by 64.8% during the first quarter. Invesco Ltd. now owns 74,388 shares of the company's stock worth $33,000 after acquiring an additional 29,256 shares during the period. Bridgeway Capital Management LLC acquired a new position in shares of Verrica Pharmaceuticals during the third quarter worth about $52,000. Finally, Goldman Sachs Group Inc. increased its stake in shares of Verrica Pharmaceuticals by 23.3% during the first quarter. Goldman Sachs Group Inc. now owns 139,055 shares of the company's stock worth $61,000 after acquiring an additional 26,308 shares during the period. Hedge funds and other institutional investors own 42.45% of the company's stock.

About Verrica Pharmaceuticals

Verrica Pharmaceuticals Inc is a clinical‐stage biopharmaceutical company focused on the development and commercialization of topical therapies for dermatological conditions. Its lead investigational product, VP-102, is a standardized formulation of cantharidin in a pre-measured applicator designed to treat molluscum contagiosum and common warts. Verrica's approach emphasizes consistency of dosing and patient convenience, aiming to improve upon off‐label use of existing treatments.

Beyond VP-102, Verrica is advancing VP-103, a next‐generation topical candidate intended to optimize tolerability while maintaining efficacy against viral skin lesions.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Add As Preferred Source